Final overall survival analysis from the phase 3 INAVO120 study demonstrates that first-line inavolisib in combination with standard-of care palbociclib-fulvestrant…
INAVO120
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
